A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Study of Emi-Le in Participants with Solid Tumors

Trial Details

NCT ID
NCT05377996
Phase
PHASE1 / PHASE2
Sponsor
Day One Biopharmaceuticals, Inc.
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • XMT-1660
Locations (sample)
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Orange, California, United States|33.78779,-117.85311
  • San Francisco, California, United States|37.77493,-122.41942
  • Santa Monica, California, United States|34.01949,-118.49138
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Recurrent or advanced solid tumor and has disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Participants in DES must have at least one measurable disease (target) lesion as defined by RECIST version 1.1.
  • Tumor tissue, either archival or from a fresh tumor biopsy, available for testing or be willing to undergo a minimally invasive tumor biopsy to obt…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →